Tonogenchoncel-L

Drug Profile

Tonogenchoncel-L

Alternative Names: Invossa; TG C; TGF-beta-1 gene therapy - TissueGene; TissueGene-C; TissueGene-C(S); Transforming growth factor-beta-1 gene therapy - TissueGene

Latest Information Update: 14 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TissueGene
  • Developer Kolon Life Science; TissueGene
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Osteoarthritis

Most Recent Events

  • 12 Jul 2017 Registered for Osteoarthritis in South Korea (Intra-articular)
  • 01 Nov 2016 Preregistration for Osteoarthritis in South Korea (Intra-articular)
  • 01 Nov 2016 Tonogenchoncel-L licensed to Mitsubishi Tanabe Pharma Corporation in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top